Just recently we issued a paper concerning drawbacks of US patent prosecution (see our previous blogs) and now JURISTAT published a new analysis on the After Final Consideration Pilot (AFCP) 2.0. In 2013, USPTO enacted the program as an alternative response to a final rejection. The goal of the program was to increase communication between ... Read More
In the legal dispute between the bicycle bag manufacturer ORTLIEB and AMAZON, the German Supreme Court (BGH) has now handed down a landmark decision and Ortlieb has long defended itself against the practice that when customers enter „Ortlieb bicycle bags“, they end up at Amazon, where they are also shown other offers from other manufacturers, ... Read More
Clients have been saying for several years that it would have taken less time and money to obtain a US patent in the past. Now one could say that it is a purely subjective perception and in retrospect „the good old days“ were always better. However, the observation that US examination procedures take longer and ... Read More
At the invitation of Prof. Pascual SEGURA, Professor at the UB Patent Center of the University of Barcelona, Bernd FABRY, CEO of IP2 Patentanwalts GmbH, gave around 80 lawyers and law students an overview of German employee invention law at the „Lunes de Patentes“ event, in particular with regard to employer obligations, inventors compensation and ... Read More
With the good name of sport stars, good money can still be earned – even if this takes place in the grey area of the legally permissible. Boris Becker can sing a song about it and now the Brazilian superstar Neymar has had to learn how quickly the right to his own name can be ... Read More
Supplemental Protection Certificates (SPC) can extend a patent right for a maximum of five years. A six-month additional extension is available in accordance with Regulation (EC) No 1901/2006 if the SPC relates to a medicinal product for children for which data has been submitted according to a Pediatric Investigation Plan (PIP). PIPs are required to ... Read More
Ticagrelor (trade name Brilinta, Brilique, and Possia) is a blockbuster drug produced by AstraZeneca with total sales of $1,079m in 2017. Ticagrelor: is a platelet aggregation inhibitor and is used for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation.
Dear Sir and Madam, Dear clients: We are pleased to announce that IP2 Patentanwalts GmbH is in the process of opening the next chapter in its history: As of January 1, 2019, we announce the association with our US colleagues Dilworth & Barrese, LLP. With this step, we will be able to offer all aspects ... Read More